Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network

Hilka Rauert-Wunderlich, Anja Mottok, David W. Scott, Lisa Rimsza, German Ott, Wolfram Klapper, Michael Unterhalt, Hanneke C. Kluin-Nelemans, Olivier Hermine, Sylvia Hartmann, Christoph Thorns, Grzegorz Rymkiewicz, Harald Holte, Martin Dreyling, Eva Hoster, Andreas Rosenwald

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Mantle cell lymphoma (MCL) is still considered incurable and the course of the disease is highly variable. Established risk factors include the Mantle Cell Lymphoma International Prognostic Index (MIPI) and the quantification of the proliferation rate of the tumour cells, e.g. by Ki-67 immunohistochemistry. In this study, we aimed to validate the prognostic value of the gene expression-based MCL35 proliferation assay in patient cohorts from randomized trials of the European Mantle Cell Lymphoma Network. Using this assay, we analysed the gene expression proliferation signature in routine diagnostic lymph node specimens from MCL Younger and MCL Elderly trial patients, and the calculated MCL35 score was used to assign MCL patients to low (61%), standard (27%) or high (12%) risk groups with significantly different outcomes. We confirm here in our prospective clinical trial cohort of MCL patients, that the MCL35 assay is strongly prognostic, providing additional information to the Ki-67 index and the MIPI. Thus, this robust assay may assist in making treatment decisions or in devising risk-adapted prospective clinical trials in the future.

Original languageEnglish (US)
JournalBritish Journal of Haematology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Mantle-Cell Lymphoma
Gene Expression
Clinical Trials
Transcriptome
Decision Making
Lymph Nodes
Immunohistochemistry

Keywords

  • gene expression analysis
  • mantle cell lymphoma
  • prognostic biomarker
  • proliferation signature
  • risk group stratification

ASJC Scopus subject areas

  • Hematology

Cite this

Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. / Rauert-Wunderlich, Hilka; Mottok, Anja; Scott, David W.; Rimsza, Lisa; Ott, German; Klapper, Wolfram; Unterhalt, Michael; Kluin-Nelemans, Hanneke C.; Hermine, Olivier; Hartmann, Sylvia; Thorns, Christoph; Rymkiewicz, Grzegorz; Holte, Harald; Dreyling, Martin; Hoster, Eva; Rosenwald, Andreas.

In: British Journal of Haematology, 01.01.2018.

Research output: Contribution to journalArticle

Rauert-Wunderlich, H, Mottok, A, Scott, DW, Rimsza, L, Ott, G, Klapper, W, Unterhalt, M, Kluin-Nelemans, HC, Hermine, O, Hartmann, S, Thorns, C, Rymkiewicz, G, Holte, H, Dreyling, M, Hoster, E & Rosenwald, A 2018, 'Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network', British Journal of Haematology. https://doi.org/10.1111/bjh.15519
Rauert-Wunderlich, Hilka ; Mottok, Anja ; Scott, David W. ; Rimsza, Lisa ; Ott, German ; Klapper, Wolfram ; Unterhalt, Michael ; Kluin-Nelemans, Hanneke C. ; Hermine, Olivier ; Hartmann, Sylvia ; Thorns, Christoph ; Rymkiewicz, Grzegorz ; Holte, Harald ; Dreyling, Martin ; Hoster, Eva ; Rosenwald, Andreas. / Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. In: British Journal of Haematology. 2018.
@article{965a71b199e643cc82dfffe1134c49fc,
title = "Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network",
abstract = "Mantle cell lymphoma (MCL) is still considered incurable and the course of the disease is highly variable. Established risk factors include the Mantle Cell Lymphoma International Prognostic Index (MIPI) and the quantification of the proliferation rate of the tumour cells, e.g. by Ki-67 immunohistochemistry. In this study, we aimed to validate the prognostic value of the gene expression-based MCL35 proliferation assay in patient cohorts from randomized trials of the European Mantle Cell Lymphoma Network. Using this assay, we analysed the gene expression proliferation signature in routine diagnostic lymph node specimens from MCL Younger and MCL Elderly trial patients, and the calculated MCL35 score was used to assign MCL patients to low (61{\%}), standard (27{\%}) or high (12{\%}) risk groups with significantly different outcomes. We confirm here in our prospective clinical trial cohort of MCL patients, that the MCL35 assay is strongly prognostic, providing additional information to the Ki-67 index and the MIPI. Thus, this robust assay may assist in making treatment decisions or in devising risk-adapted prospective clinical trials in the future.",
keywords = "gene expression analysis, mantle cell lymphoma, prognostic biomarker, proliferation signature, risk group stratification",
author = "Hilka Rauert-Wunderlich and Anja Mottok and Scott, {David W.} and Lisa Rimsza and German Ott and Wolfram Klapper and Michael Unterhalt and Kluin-Nelemans, {Hanneke C.} and Olivier Hermine and Sylvia Hartmann and Christoph Thorns and Grzegorz Rymkiewicz and Harald Holte and Martin Dreyling and Eva Hoster and Andreas Rosenwald",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/bjh.15519",
language = "English (US)",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network

AU - Rauert-Wunderlich, Hilka

AU - Mottok, Anja

AU - Scott, David W.

AU - Rimsza, Lisa

AU - Ott, German

AU - Klapper, Wolfram

AU - Unterhalt, Michael

AU - Kluin-Nelemans, Hanneke C.

AU - Hermine, Olivier

AU - Hartmann, Sylvia

AU - Thorns, Christoph

AU - Rymkiewicz, Grzegorz

AU - Holte, Harald

AU - Dreyling, Martin

AU - Hoster, Eva

AU - Rosenwald, Andreas

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Mantle cell lymphoma (MCL) is still considered incurable and the course of the disease is highly variable. Established risk factors include the Mantle Cell Lymphoma International Prognostic Index (MIPI) and the quantification of the proliferation rate of the tumour cells, e.g. by Ki-67 immunohistochemistry. In this study, we aimed to validate the prognostic value of the gene expression-based MCL35 proliferation assay in patient cohorts from randomized trials of the European Mantle Cell Lymphoma Network. Using this assay, we analysed the gene expression proliferation signature in routine diagnostic lymph node specimens from MCL Younger and MCL Elderly trial patients, and the calculated MCL35 score was used to assign MCL patients to low (61%), standard (27%) or high (12%) risk groups with significantly different outcomes. We confirm here in our prospective clinical trial cohort of MCL patients, that the MCL35 assay is strongly prognostic, providing additional information to the Ki-67 index and the MIPI. Thus, this robust assay may assist in making treatment decisions or in devising risk-adapted prospective clinical trials in the future.

AB - Mantle cell lymphoma (MCL) is still considered incurable and the course of the disease is highly variable. Established risk factors include the Mantle Cell Lymphoma International Prognostic Index (MIPI) and the quantification of the proliferation rate of the tumour cells, e.g. by Ki-67 immunohistochemistry. In this study, we aimed to validate the prognostic value of the gene expression-based MCL35 proliferation assay in patient cohorts from randomized trials of the European Mantle Cell Lymphoma Network. Using this assay, we analysed the gene expression proliferation signature in routine diagnostic lymph node specimens from MCL Younger and MCL Elderly trial patients, and the calculated MCL35 score was used to assign MCL patients to low (61%), standard (27%) or high (12%) risk groups with significantly different outcomes. We confirm here in our prospective clinical trial cohort of MCL patients, that the MCL35 assay is strongly prognostic, providing additional information to the Ki-67 index and the MIPI. Thus, this robust assay may assist in making treatment decisions or in devising risk-adapted prospective clinical trials in the future.

KW - gene expression analysis

KW - mantle cell lymphoma

KW - prognostic biomarker

KW - proliferation signature

KW - risk group stratification

UR - http://www.scopus.com/inward/record.url?scp=85052431790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052431790&partnerID=8YFLogxK

U2 - 10.1111/bjh.15519

DO - 10.1111/bjh.15519

M3 - Article

C2 - 30095158

AN - SCOPUS:85052431790

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -